HAVCR2 and head and neck squamous cell carcinoma: Currently, TIM-3 and LAG-3 blocking monoclonal antibodies are being evaluated in a number of clinical trials as monotherapy and in combination with anti-PD-1:PD-L1 therapies in HNSCC [23,24].